| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Collegium Pharmaceutical, Inc. (COLL) has 13 insiders with recent SEC Form 4 filings, including 0 buys and 17 sells. COLL is classified in the Pharmaceuticals industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 3.13M | $119.26M | - | |
| CFO | 126.7K | $4.82M | - | |
| VP | 121.2K | $4.61M | - | |
| CEO | 97.0K | $3.69M | - | |
| Dir | 95.0K | $3.62M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 6, 2025 | Dreyer Scott54 | EVP &Chief Commercial Officer | Sell | 15,387 | $30.00 | $461,671.55 | -10.8% | -1.3% | +25.0% | |
| Mar 6, 2025 | Kuhlmann Shirley R.49 | EVP And General Counsel | Sale+OE | 86,067 | $28.19 | $2,426,633.99 | -17.8% | -1.3% | +25.0% | |
| Jan 10, 2025 | Kuhlmann Shirley R.49 | EVP And General Counsel | Sale+OE | 27,500 | $33.04 | $908,627.77 | -10.1% | -25.0% | +38.4% | |
| Sep 13, 2024 | Smith Thomas B60 | EVP And Chief Medical Officer | Sell | 9,593 | $36.62 | $351,319.64 | -15.1% | -19.8% | -0.5% | |
| Sep 6, 2024 | Kuhlmann Shirley R.49 | EVP And General Counsel | Sell | 20,225 | $38.26 | $773,791.80 | -5.3% | -19.7% | +3.0% | |
| Jun 3, 2024 | Kuhlmann Shirley R.49 | EVP And General Counsel | Sell | 25,000 | $32.57 | $814,180.12 | -8.2% | +16.0% | -9.4% | |
| May 28, 2024 | Tupper Colleen45 | EVP &Chief Financial Officer | Sell | 19,710 | $34.21 | $674,367.80 | -13.1% | +9.3% | -15.9% | |
| May 24, 2024 | Dreyer Scott54 | EVP &Chief Commercial Officer | Sale+OE | 108,016 | $33.91 | $3,662,548.45 | -30.6% | +5.2% | -15.7% | |
| May 14, 2024 | Bohlin Garen G | Director | Sale+OE | 28,985 | $32.30 | $936,311.15 | -39.3% | +7.0% | -12.7% | |
| Feb 29, 2024 | Smith Thomas B60 | EVP And Chief Medical Officer | Sell | 995 | $36.76 | $36,580.18 | -1.5% | -9.6% | -20.9% |